Biotech
-
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although…
Read More » -
Biotech startups are built on venture capital. Track funding rounds here.
Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into…
Read More » -
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a…
Read More » -
How a Biogen drug set the stage for a new biotech targeting ALS
Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke with…
Read More » -
‘Find any advantage’: 3 biotech leaders on driving R&D success
“Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel…
Read More » -
Amgen shares sink on obesity drug concerns; AstraZeneca to spend $3.5B on manufacturing
An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis struck drug discovery deals.
Read More » -
Cigna confirms it is not pursuing Humana acquisition
The formal denial comes after Cigna CEO David Cordani tried to push back on persistent speculation of a Humana merger…
Read More » -
Kalaris to go public via reverse merger with AlloVir
After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related macular degeneration.
Read More » -
Sarepta scraps a Duchenne drug as gene therapy sales rise
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning…
Read More » -
Sana to lay off staff, deepen autoimmune focus in latest retrenchment
The company, which is only three years removed from one of biotech’s most lucrative IPOs, will cut jobs for a…
Read More »